Connect with us


Futures Slide After Trump Opens A “Most Unwelcome Can Of Worms” With TikTok, WeChat Executive Order

Futures Slide After Trump Opens A "Most Unwelcome Can Of Worms" With TikTok, WeChat Executive Order



Futures Slide After Trump Opens A "Most Unwelcome Can Of Worms" With TikTok, WeChat Executive Order Tyler Durden Fri, 08/07/2020 - 07:19

World stocks ended a four day rally overnight that pushed the MSCI World index to green for the year, after U.S. President Trump cranked up simmering tensions with China after late on Thursday has signed orders to ban Americans from transactions involving China’s ByteDance (TikTok’s parent) and WeChat (owned by Tencent), taking effect in 45 days. Furthermore, Trump’s Working Group on Financial Markets recommended that Chinese companies currently listed on US exchanges should be delisted if they do not become compliant with US accounting standards.

Tencent Holdings slumped 5% in Hong Kong after plunging as much as the 10% limit earlier.

Trump's decision to take aim at WeChat, the world’s most-used messaging app, has the potential to upend the international businesses of companies from Apple Inc. to Walmart Inc.

“The executive orders leveled on TikTok and the scrutiny over WeChat has opened up a most unwelcome can of worms," said Stephen Innes, chief global markets strategist at AxiCorp. This could “be more of a signal than anything else, especially front-running the China trade talks” expected later this month, he said.

S&P futures pared some of their Thursday gains after the ES continued to print new post-COVID highs in late US trade on Thursday; the Emini hit a high of just shy of 3350, ahead of its ATH just beneath 3400.

MSCI’s index of world stocks fell 0.2% on Friday after up four consecutive days of gains. It was less than 3% away from a late February peak, and had just turned green on the year on Thursday.  European stocks opened lower, with major indexes down between 0.2% to 0.4% in early trading, although they largely brushed off Asia’s tech-led slump. The Eurostoxx 600 is little changed as gains in telecoms and media are offset by weaker autos and oil & gas names. FTSE MIB and IBEX underperform.

Chinese stocks led losers in Asia and the yuan slumped after Trump issued the executive orders, noting that his admin was stepping up efforts to purge “untrusted” Chinese apps from U.S. digital networks and called TikTok and WeChat “significant threats.” “The U.S. pressure on China’s tech sector appears likely to continue in the presidential elections, injecting volatility in the sector and opening the door to escalatory retaliation,” UBS strategists said.

In addition to the TikTok crackdown, Trump confirmed he has signed proclamation re-imposing aluminium tariffs on Canada, to which Canada has said it would retaliate. However, as NewsSquawk notes, the measures appear more symbolic/political for now than part of a broader economic concern.

Meanwhile, concerns remain that lawmakers won’t be able to resolve differences over a new U.S. relief package. The White House and congressional Democrats are up against a self-imposed Friday deadline to strike a deal. Markets will also be closely watching details from the monthly U.S. jobs report today (full preview here), which is expected to show a steep slowdown in hiring during July.

In rates, there is a modest bull-flattening bias in Treasuries, 2s unch. At 11.5bps, 10s -2bps at 52bps and 30s -3bps at 117bps; the strength was made in futures overnight amid the escalating Sino-US tensions.

In FX, the dollar strengthened, while gold retreated for the first time in six days. The subdued risk tone has seen the Dollar Index reclaim the 93 handle after the late risk rally on Thursday kept it away, seeing cyclical currencies and EMFX on the defensive. Turkey’s lira slumped to a record low against the dollar even after the central bank spent billions to to prop it up, although a late burst pushed the battered currency to unchanged.

Sterling fell after a post-BOE advance on Thursday, as traders take stock of officials distancing themselves from negative rates and an optimistic view of the U.K’s economic recovery. The Australian currency weakened after dovish remarks from the Reserve Bank and the escalation of the U.S.-China row weighed on the currency. The New Zealand dollar followed suit, seeing the biggest losses in the G-10. The Norwegian krone follow oil and gold prices lower, although a mid-week spike in the commodities helped make the currency see the biggest weekly gains among its peers against the greenback.

In commodities, crude futures have been moving slightly lower through Europe, although by no means significant, with oil demand more sheltered from the US-China tech battle. Gold and silver have faded some of their record gains, with silver dropping modestly after rising just shy of $30 late on Thursday.

Economic data include the monthly employment report for July. Dish and Brookfield Renewable Partners are due to report earnings.

Market Snapshot

  • S&P 500 futures down 0.5% to 3,327.50
  • STOXX Europe 600 down 0.1% to 362.08
  • MXAP down 0.6% to 168.82
  • MXAPJ down 0.9% to 563.20
  • Nikkei down 0.4% to 22,329.94
  • Topix down 0.2% to 1,546.74
  • Hang Seng Index down 1.6% to 24,531.62
  • Shanghai Composite down 1% to 3,354.04
  • Sensex down 0.05% to 38,007.48
  • Australia S&P/ASX 200 down 0.6% to 6,004.84
  • Kospi up 0.4% to 2,351.67
  • German 10Y yield fell 0.6 bps to -0.537%
  • Euro down 0.4% to $1.1829
  • Brent Futures down 0.4% to $44.89/bbl
  • Italian 10Y yield fell 4.1 bps to 0.806%
  • Spanish 10Y yield fell 0.3 bps to 0.276%
  • Brent futures down 0.8% to $44.74/bbl
  • Gold spot down 0.1% to $2,060.74
  • U.S. Dollar Index up 0.3% to 93.10

Top Overnight News from Bloomberg

  • President Donald Trump signed a pair of executive orders prohibiting U.S. residents from doing business with the Chinese- owned TikTok and WeChat apps beginning 45 days from now, citing the national security risk of leaving Americans’ personal data exposed
  • The Trump administration’s move to ban U.S. residents from doing business with Tencent Holdings Ltd.’s WeChat app erased $30 billion from the Internet giant’s market value and sent the yuan to its biggest slump in two weeks
  • Hopes for a speedy economic rebound in large parts of Europe are holding ground as manufacturing starts to recover from pandemic lows. Industrial output in Germany rose at a faster-than-expected pace of 8.9% in June, and factory demand is also increasing. With France and Spain experiencing similar trends, signs are mounting that Europe’s initial bounce-back from the worst recession in living memory may be faster than anticipated
  • OPEC’s second biggest producer Iraq made its strongest commitment yet to implement deep cuts in crude production after the country’s oil minister and his Saudi counterpart held a phone call Thursday. The country failed to meet its production-cut target in May and June

Asian equity markets failed to sustain the positive handover from Wall St where all major indices notched gains as tech resumed its outperformance and Apple continued to print fresh record highs to edge closer towards the USD 2tln market cap status, while sentiment stateside was also underpinned by lower jobless claims data and with COVID-sensitive sectors such as airlines, hotels and casinos supported in late trade after the US State Department lifted advisory against all international travel and returned to its previous system of country specific levels of travel advice. Nonetheless, the momentum faded in Asia with the region cautious heading into the latest Chinese trade data which later proved to be mostly better than expected and with US-China tensions stoked after US President Trump signed executive orders to ban transactions with TikTok’s parent ByteDance, as well as Tencent-owned WeChat in 45 days. ASX 200 (-0.6%) and Nikkei 225 (-0.4%) were both negative in which Australia’s mining names gave back some of their recent gains and as Japan digested earnings, with sentiment also dampened by concerns of a weaker consumer as although Household Spending in June rose by its fastest pace since data was made available in 2000, the actual decline in household spending for the April-June quarter of 9.8% Y/Y was the steepest contraction on record. Hang Seng (-1.8%) and Shanghai Comp. (-0.9%) conformed to the downbeat tone due to the US recent actions against TikTok and WeChat which saw Tencent shares slump over 7%, while US President’s Working Group on Financial Markets earlier recommended Chinese companies currently listed on US exchanges to be compliant with US accounting standards or be delisted. Finally, 10yr JGBs were relatively flat with minimal gains seen amid the risk averse tone and the BoJ present in the market for JPY 940bln of JGBs focused on 1yr-3yr and 5yr-10yr maturities.

Top Asian News

  • Japan Looks to Scrap New Libor-Tied Lending Six Months Early
  • China Official Reserves Rise to Highest Since July 2016

European stocks are modestly softer [Euro Stoxx 50 -0.3%] as the downbeat APAC performance seeps into the region after China lodged stern opposition to the US’ executive order on China’s TikTok and WeChat, alongside the State’s drone sale to Taiwan. Broader sectors are mixed with underperformance seen in the energy sector amid losses in the complex, whilst Telecoms remain firm as Deutsche Telekom (+2.8%) holds onto gains amid stellar numbers from T-Mobile (+5.5% pre-mkt) of which Deutsche Telekom owns 43.5%. The sectoral breakdown adds little meat to the bones and provides no clear risk bias, whilst the Travel & Leisure sector remain pressured amid fears of further additions to quarantine lists prompting travel cancellations. In terms of individual movers: BP (-2.6%) trades lower as sources stated that it is poised to sell a large chunk of its oil and gas assets even if crude prices rise; oil giants usually hold assets in the longer-term even if prices fall – with a view of bringing marginal production online contingent on improving market conditions. Rolls-Royce (-3.4%) is hit on the back of source reports that activist investor ValueAct has reportedly sold its entire 10.9% stake in the group since 2017. Finally, Hikma Pharmaceuticals (+9%) extended on gains after raising its FY20 generic revenue guidance alongside its operating margin, whilst the CEO later stated that the group entered a manufacturing deal for Gilead’s remdesivir treatment, potentially providing added impetus.

Top European News

  • Standard Life Loses Top Spot Among U.K. Asset Managers
  • SAS Makes Last-Ditch Bid to Secure Backing for Rescue Plan
  • TP ICAP Says July Trading Activity ‘Materially Lower’ Than 2019

In FX, the Dollar continues to benefit from corrective and positional trade rather than any real fundamental shift in sentiment or direction, as consolidation and short covering persists pre-NFP and the showdown talks in Washington to resolve differences on the next relief bill. It’s debatable whether the monthly BLS report or fiscal deadline will be Friday’s headline-grabbing event, but for now the Buck has clawed back more lost ground against G10 peers and the index is holding between 93.227-92.759 parameters, above Thursday’s 92.495 new 2020 low.

  • NZD/EUR/CHF/CAD - The major victims of the Greenback’s ongoing recuperation, if not quite revival, as the Kiwi backs off from a test of resistance/offers into 0.6700 and the Euro fades into 1.1900 where 1.5 bn option expiries reside. Note also, the single currency has found ventures above the round number unsustainable and is now south of almost equally large expiry interest at 1.1850 (1.2 bn), with bids said to be underpinning around 1.1820-10 and a key Fib in close proximity (1.1823). Meanwhile, the Franc remains sub-0.9100 and straddling 1.0800 vs the Euro as SNB reserves data reveal a decline, and the Loonie has reversed further towards 1.3400 from recent 1.3250+ multi-month highs following the reintroduction of US tariffs on Canadian aluminium and impending like-for-like countermeasures. More immediately, the 2 NA nations go head-to-head on the jobs front with July data due simultaneously ahead of Canada’s Ivey PMIs.
  • AUD/GBP - Also down vs their US counterpart, but clinging to or near big figure/psychological levels at 0.7200 and 1.3100 respectively, as the Aussie draws some underlying support from encouraging or arguably upbeat Chinese trade data and the Pound retains an element of post-BoE strength even though MPC member Ramsden leaves the door open for more stimulus in November should the need arise. For the record, no major reaction down under to the RBA’s SOMP or comments from Deputy Governor Ellis largely underlining latest policy meeting assessments and guidance.
  • JPY - Still no big make or break for the Yen that is pivoting 105.50 after a late fixed related recoil yesterday and Japanese reserves showing a rise conducive with, but not conclusive, a degree of official intervention, albeit this time around 100 pips above the low 104.00 area.
  • EM - Simply no respite for the Lira that has crashed to fresh all time depths against the Dollar and Euro for that matter, even though the CBRT has started withdrawing liquidity provisions and instructing banks to use the overnight lending facility at 9.75% ahead of a 50% reduction in primary dealer OMO limits as from Monday. Usd/Try paring back a tad from 7.3650 or so.      

In commodities, WTI and Brent front month futures drift lower in a correlated move with the equity markets as news-flow for the complex remains scarce ahead of the US jobs report. An earlier Saudi-Iraq statement did the rounds but provided no fresh substance – with the two nations reaffirming their commitment to the OPEC+ pact. WTI Sept resides around USD 41.50/bbl having had briefly dipped below the figure, whilst Brent Oct lost its 45/bbl-status after oscillating on either side of the figure in early hours. Elsewhere, spot gold is relatively uneventful and remains contained around the USD 2060/oz mark, as has been the case throughout the European morning, whilst spot silver sees more pronounced losses as price consolidate from yesterday’s outperformance.  In terms of base metals, Dalian iron ore prices retreated overnight following yesterday’s warning from the Dalian exchange around investing rationally amid the recent rally, whilst Shanghai copper saw losses as US-Sino tensions continue to ratchet.

US Event Calendar

  • 8:30am: Change in Nonfarm Payrolls, est. 1.48m, prior 4.8m
    • Change in Private Payrolls, est. 1.18m, prior 4.77m
    • Average Hourly Earnings MoM, est. -0.5%, prior -1.2%
    • Average Hourly Earnings YoY, est. 4.2%, prior 5.0%
    • Average Weekly Hours All Employees, est. 34.4, prior 34.5
    • Unemployment Rate, est. 10.55%, prior 11.1%
    • Labor Force Participation Rate, est. 61.8%, prior 61.5%
    • Underemployment Rate, prior 18.0%
  • 10am: Wholesale Inventories MoM, est. -2.0%, prior -2.0%; Wholesale Trade Sales MoM, prior 5.4%
  • 3pm: Consumer Credit, est. $10.0b, prior $18.3b deficit

Read More

Continue Reading


Looking Back At COVID’s Authoritarian Regimes

After having moved from Canada to the United States, partly to be wealthier and partly to be freer (those two are connected, by the way), I was shocked,…



After having moved from Canada to the United States, partly to be wealthier and partly to be freer (those two are connected, by the way), I was shocked, in March 2020, when President Trump and most US governors imposed heavy restrictions on people’s freedom. The purpose, said Trump and his COVID-19 advisers, was to “flatten the curve”: shut down people’s mobility for two weeks so that hospitals could catch up with the expected demand from COVID patients. In her book Silent Invasion, Dr. Deborah Birx, the coordinator of the White House Coronavirus Task Force, admitted that she was scrambling during those two weeks to come up with a reason to extend the lockdowns for much longer. As she put it, “I didn’t have the numbers in front of me yet to make the case for extending it longer, but I had two weeks to get them.” In short, she chose the goal and then tried to find the data to justify the goal. This, by the way, was from someone who, along with her task force colleague Dr. Anthony Fauci, kept talking about the importance of the scientific method. By the end of April 2020, the term “flatten the curve” had all but disappeared from public discussion.

Now that we are four years past that awful time, it makes sense to look back and see whether those heavy restrictions on the lives of people of all ages made sense. I’ll save you the suspense. They didn’t. The damage to the economy was huge. Remember that “the economy” is not a term used to describe a big machine; it’s a shorthand for the trillions of interactions among hundreds of millions of people. The lockdowns and the subsequent federal spending ballooned the budget deficit and consequent federal debt. The effect on children’s learning, not just in school but outside of school, was huge. These effects will be with us for a long time. It’s not as if there wasn’t another way to go. The people who came up with the idea of lockdowns did so on the basis of abstract models that had not been tested. They ignored a model of human behavior, which I’ll call Hayekian, that is tested every day.

These are the opening two paragraphs of my latest Defining Ideas article, “Looking Back at COVID’s Authoritarian Regimes,” Defining Ideas, March 14, 2024.

Another excerpt:

That wasn’t the only uncertainty. My daughter Karen lived in San Francisco and made her living teaching Pilates. San Francisco mayor London Breed shut down all the gyms, and so there went my daughter’s business. (The good news was that she quickly got online and shifted many of her clients to virtual Pilates. But that’s another story.) We tried to see her every six weeks or so, whether that meant our driving up to San Fran or her driving down to Monterey. But were we allowed to drive to see her? In that first month and a half, we simply didn’t know.

Read the whole thing, which is longer than usual.


Read More

Continue Reading


Problems After COVID-19 Vaccination More Prevalent Among Naturally Immune: Study

Problems After COVID-19 Vaccination More Prevalent Among Naturally Immune: Study

Authored by Zachary Stieber via The Epoch Times (emphasis…



Problems After COVID-19 Vaccination More Prevalent Among Naturally Immune: Study

Authored by Zachary Stieber via The Epoch Times (emphasis ours),

People who recovered from COVID-19 and received a COVID-19 shot were more likely to suffer adverse reactions, researchers in Europe are reporting.

A medical worker administers a dose of the Pfizer-BioNTech COVID-19 vaccine to a patient at a vaccination center in Ancenis-Saint-Gereon, France, on Nov. 17, 2021. (Stephane Mahe//Reuters)

Participants in the study were more likely to experience an adverse reaction after vaccination regardless of the type of shot, with one exception, the researchers found.

Across all vaccine brands, people with prior COVID-19 were 2.6 times as likely after dose one to suffer an adverse reaction, according to the new study. Such people are commonly known as having a type of protection known as natural immunity after recovery.

People with previous COVID-19 were also 1.25 times as likely after dose 2 to experience an adverse reaction.

The findings held true across all vaccine types following dose one.

Of the female participants who received the Pfizer-BioNTech vaccine, for instance, 82 percent who had COVID-19 previously experienced an adverse reaction after their first dose, compared to 59 percent of females who did not have prior COVID-19.

The only exception to the trend was among males who received a second AstraZeneca dose. The percentage of males who suffered an adverse reaction was higher, 33 percent to 24 percent, among those without a COVID-19 history.

Participants who had a prior SARS-CoV-2 infection (confirmed with a positive test) experienced at least one adverse reaction more often after the 1st dose compared to participants who did not have prior COVID-19. This pattern was observed in both men and women and across vaccine brands,” Florence van Hunsel, an epidemiologist with the Netherlands Pharmacovigilance Centre Lareb, and her co-authors wrote.

There were only slightly higher odds of the naturally immune suffering an adverse reaction following receipt of a Pfizer or Moderna booster, the researchers also found.

The researchers performed what’s known as a cohort event monitoring study, following 29,387 participants as they received at least one dose of a COVID-19 vaccine. The participants live in a European country such as Belgium, France, or Slovakia.

Overall, three-quarters of the participants reported at least one adverse reaction, although some were minor such as injection site pain.

Adverse reactions described as serious were reported by 0.24 percent of people who received a first or second dose and 0.26 percent for people who received a booster. Different examples of serious reactions were not listed in the study.

Participants were only specifically asked to record a range of minor adverse reactions (ADRs). They could provide details of other reactions in free text form.

“The unsolicited events were manually assessed and coded, and the seriousness was classified based on international criteria,” researchers said.

The free text answers were not provided by researchers in the paper.

The authors note, ‘In this manuscript, the focus was not on serious ADRs and adverse events of special interest.’” Yet, in their highlights section they state, “The percentage of serious ADRs in the study is low for 1st and 2nd vaccination and booster.”

Dr. Joel Wallskog, co-chair of the group React19, which advocates for people who were injured by vaccines, told The Epoch Times: “It is intellectually dishonest to set out to study minor adverse events after COVID-19 vaccination then make conclusions about the frequency of serious adverse events. They also fail to provide the free text data.” He added that the paper showed “yet another study that is in my opinion, deficient by design.”

Ms. Hunsel did not respond to a request for comment.

She and other researchers listed limitations in the paper, including how they did not provide data broken down by country.

The paper was published by the journal Vaccine on March 6.

The study was funded by the European Medicines Agency and the Dutch government.

No authors declared conflicts of interest.

Some previous papers have also found that people with prior COVID-19 infection had more adverse events following COVID-19 vaccination, including a 2021 paper from French researchers. A U.S. study identified prior COVID-19 as a predictor of the severity of side effects.

Some other studies have determined COVID-19 vaccines confer little or no benefit to people with a history of infection, including those who had received a primary series.

The U.S. Centers for Disease Control and Prevention still recommends people who recovered from COVID-19 receive a COVID-19 vaccine, although a number of other health authorities have stopped recommending the shot for people who have prior COVID-19.

Another New Study

In another new paper, South Korean researchers outlined how they found people were more likely to report certain adverse reactions after COVID-19 vaccination than after receipt of another vaccine.

The reporting of myocarditis, a form of heart inflammation, or pericarditis, a related condition, was nearly 20 times as high among children as the reporting odds following receipt of all other vaccines, the researchers found.

The reporting odds were also much higher for multisystem inflammatory syndrome or Kawasaki disease among adolescent COVID-19 recipients.

Researchers analyzed reports made to VigiBase, which is run by the World Health Organization.

Based on our results, close monitoring for these rare but serious inflammatory reactions after COVID-19 vaccination among adolescents until definitive causal relationship can be established,” the researchers wrote.

The study was published by the Journal of Korean Medical Science in its March edition.

Limitations include VigiBase receiving reports of problems, with some reports going unconfirmed.

Funding came from the South Korean government. One author reported receiving grants from pharmaceutical companies, including Pfizer.

Tyler Durden Fri, 03/15/2024 - 05:00

Read More

Continue Reading


‘Excess Mortality Skyrocketed’: Tucker Carlson and Dr. Pierre Kory Unpack ‘Criminal’ COVID Response

‘Excess Mortality Skyrocketed’: Tucker Carlson and Dr. Pierre Kory Unpack ‘Criminal’ COVID Response

As the global pandemic unfolded, government-funded…



'Excess Mortality Skyrocketed': Tucker Carlson and Dr. Pierre Kory Unpack 'Criminal' COVID Response

As the global pandemic unfolded, government-funded experimental vaccines were hastily developed for a virus which primarily killed the old and fat (and those with other obvious comorbidities), and an aggressive, global campaign to coerce billions into injecting them ensued.

Then there were the lockdowns - with some countries (New Zealand, for example) building internment camps for those who tested positive for Covid-19, and others such as China welding entire apartment buildings shut to trap people inside.

It was an egregious and unnecessary response to a virus that, while highly virulent, was survivable by the vast majority of the general population.

Oh, and the vaccines, which governments are still pushing, didn't work as advertised to the point where health officials changed the definition of "vaccine" multiple times.

Tucker Carlson recently sat down with Dr. Pierre Kory, a critical care specialist and vocal critic of vaccines. The two had a wide-ranging discussion, which included vaccine safety and efficacy, excess mortality, demographic impacts of the virus, big pharma, and the professional price Kory has paid for speaking out.

Keep reading below, or if you have roughly 50 minutes, watch it in its entirety for free on X:

"Do we have any real sense of what the cost, the physical cost to the country and world has been of those vaccines?" Carlson asked, kicking off the interview.

"I do think we have some understanding of the cost. I mean, I think, you know, you're aware of the work of of Ed Dowd, who's put together a team and looked, analytically at a lot of the epidemiologic data," Kory replied. "I mean, time with that vaccination rollout is when all of the numbers started going sideways, the excess mortality started to skyrocket."

When asked "what kind of death toll are we looking at?", Kory responded " 2023 alone, in the first nine months, we had what's called an excess mortality of 158,000 Americans," adding "But this is in 2023. I mean, we've  had Omicron now for two years, which is a mild variant. Not that many go to the hospital."

'Safe and Effective'

Tucker also asked Kory why the people who claimed the vaccine were "safe and effective" aren't being held criminally liable for abetting the "killing of all these Americans," to which Kory replied: "It’s my kind of belief, looking back, that [safe and effective] was a predetermined conclusion. There was no data to support that, but it was agreed upon that it would be presented as safe and effective."

Carlson and Kory then discussed the different segments of the population that experienced vaccine side effects, with Kory noting an "explosion in dying in the youngest and healthiest sectors of society," adding "And why did the employed fare far worse than those that weren't? And this particularly white collar, white collar, more than gray collar, more than blue collar."

Kory also said that Big Pharma is 'terrified' of Vitamin D because it "threatens the disease model." As journalist The Vigilant Fox notes on X, "Vitamin D showed about a 60% effectiveness against the incidence of COVID-19 in randomized control trials," and "showed about 40-50% effectiveness in reducing the incidence of COVID-19 in observational studies."

Professional costs

Kory - while risking professional suicide by speaking out, has undoubtedly helped save countless lives by advocating for alternate treatments such as Ivermectin.

Kory shared his own experiences of job loss and censorship, highlighting the challenges of advocating for a more nuanced understanding of vaccine safety in an environment often resistant to dissenting voices.

"I wrote a book called The War on Ivermectin and the the genesis of that book," he said, adding "Not only is my expertise on Ivermectin and my vast clinical experience, but and I tell the story before, but I got an email, during this journey from a guy named William B Grant, who's a professor out in California, and he wrote to me this email just one day, my life was going totally sideways because our protocols focused on Ivermectin. I was using a lot in my practice, as were tens of thousands of doctors around the world, to really good benefits. And I was getting attacked, hit jobs in the media, and he wrote me this email on and he said, Dear Dr. Kory, what they're doing to Ivermectin, they've been doing to vitamin D for decades..."

"And it's got five tactics. And these are the five tactics that all industries employ when science emerges, that's inconvenient to their interests. And so I'm just going to give you an example. Ivermectin science was extremely inconvenient to the interests of the pharmaceutical industrial complex. I mean, it threatened the vaccine campaign. It threatened vaccine hesitancy, which was public enemy number one. We know that, that everything, all the propaganda censorship was literally going after something called vaccine hesitancy."

Money makes the world go 'round

Carlson then hit on perhaps the most devious aspect of the relationship between drug companies and the medical establishment, and how special interests completely taint science to the point where public distrust of institutions has spiked in recent years.

"I think all of it starts at the level the medical journals," said Kory. "Because once you have something established in the medical journals as a, let's say, a proven fact or a generally accepted consensus, consensus comes out of the journals."

"I have dozens of rejection letters from investigators around the world who did good trials on ivermectin, tried to publish it. No thank you, no thank you, no thank you. And then the ones that do get in all purportedly prove that ivermectin didn't work," Kory continued.

"So and then when you look at the ones that actually got in and this is where like probably my biggest estrangement and why I don't recognize science and don't trust it anymore, is the trials that flew to publication in the top journals in the world were so brazenly manipulated and corrupted in the design and conduct in, many of us wrote about it. But they flew to publication, and then every time they were published, you saw these huge PR campaigns in the media. New York Times, Boston Globe, L.A. times, ivermectin doesn't work. Latest high quality, rigorous study says. I'm sitting here in my office watching these lies just ripple throughout the media sphere based on fraudulent studies published in the top journals. And that's that's that has changed. Now that's why I say I'm estranged and I don't know what to trust anymore."

Vaccine Injuries

Carlson asked Kory about his clinical experience with vaccine injuries.

"So how this is how I divide, this is just kind of my perception of vaccine injury is that when I use the term vaccine injury, I'm usually referring to what I call a single organ problem, like pericarditis, myocarditis, stroke, something like that. An autoimmune disease," he replied.

"What I specialize in my practice, is I treat patients with what we call a long Covid long vaxx. It's the same disease, just different triggers, right? One is triggered by Covid, the other one is triggered by the spike protein from the vaccine. Much more common is long vax. The only real differences between the two conditions is that the vaccinated are, on average, sicker and more disabled than the long Covids, with some pretty prominent exceptions to that."

Watch the entire interview above, and you can support Tucker Carlson's endeavors by joining the Tucker Carlson Network here...

Tyler Durden Thu, 03/14/2024 - 16:20

Read More

Continue Reading